Datasets

Accelerating Medicines Partnership – Alzheimer's Disease (AMP-AD)

Major public resource for AD genomics and transcriptomics. Includes ROSMAP, Mount Sinai, Mayo Clinic RNA-seq cohorts. Requires registration for access.

Last reviewed: June 1, 2026

Allen Institute / Broad Institute / Multiple academic groups

Integrates multiple published single-cell and single-nucleus datasets across diseases and control samples. Key resource for microglial state characterization in human brain.

Last reviewed: June 1, 2026

Kampmann Lab (UCSF)

MICA represents a massive functional genomic screen mapping the transcriptomic and phenotypic consequences of knocking out thousands of genes in iPSC-derived human microglia.

Last reviewed: June 3, 2026

Amit Lab (Weizmann Institute)

The foundational 2017 dataset establishing the concept of Disease-Associated Microglia (DAM). Contains the scRNA-seq mapping of homeostatic microglia transitioning into the TREM2-dependent effector state during Alzheimer's pathogenesis.

Last reviewed: June 3, 2026

Recursion Pharmaceuticals, Roche, Genentech

A machine learning-powered, high-content imaging-based map of microglial biology using whole-genome perturbation in human iPSC-derived microglia. Targeting neurological disease target discovery. Data availability not yet public at time of review.

Last reviewed: June 1, 2026

Rush Alzheimer's Disease Center (RADC)

ROSMAP is a longitudinal clinical-pathologic cohort study. It is heavily utilized in microglial computational biology because of the massive statistical power linking longitudinal cognitive scores to post-mortem multi-omics.

Last reviewed: June 2, 2026

Allen Institute, UW Medicine, Kaiser Permanente Washington

The SEA-AD atlas precisely maps the single-cell trajectory of Alzheimer's disease across all six Braak stages. Features a robust microglial sub-clustering showing the continuum of microglial states transitioning from homeostatic to disease-associated phenotypes along the cascade.

Last reviewed: June 2, 2026